Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
Francesc Bosch(Vall d'Hebron Hospital Universitari), Véronique Leblond(Sorbonne Université), Stephan Stilgenbauer(Universität Ulm), Sebastian Böttcher(University Hospital Schleswig-Holstein), Eugen Tausch(Universität Ulm), Kerstin Trunzer(Roche (Switzerland)), Andrey Zaritskey, Susan Robson(Roche (Switzerland)), Ekaterina Gresko(Roche (Switzerland)), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Mehmet Turgut(Hospital Universitari i Politècnic La Fe), Mourad Tiab(Roche (France)), Jean-Louis Merot(IQVIA (France)), Robin Foà(Sapienza University of Rome), Wolfgang Knauf(Krankenhaus Bethanien), Guy Cantin(Hôpital de l'Enfant-Jésus)
Cited by 12
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k